Ataxia

>

The NeurologyLive® Ataxia Disease Spotlight page provides in-depth updates and specific coverage on the latest data readouts and expert conversations related to the treatment and management of patients with the movement disorder.

Latest News

Investigational Vatiquinone Slows Friedreich Ataxia Disease Progression Relative to FACOMS Natural History Cohort
Investigational Vatiquinone Slows Friedreich Ataxia Disease Progression Relative to FACOMS Natural History Cohort

March 19th 2025

Two separate long-term extension studies met their pre-specified endpoints, showing highly significant evidence of sustained treatment benefits in slowing disease progression in pediatric and adult patients.

FDA Accepts NDA for Vatiquinone as Potential Treatment for Friedreich Ataxia
FDA Accepts NDA for Vatiquinone as Potential Treatment for Friedreich Ataxia

February 19th 2025

FDA Accepts NDA Application for Troriluzole as Potential First Treatment for Spinocerebellar Ataxia
FDA Accepts NDA Application for Troriluzole as Potential First Treatment for Spinocerebellar Ataxia

February 11th 2025

FDA Clears IND for Trial Assessing Gene Therapy SGT-212 in Friedreich Ataxia
FDA Clears IND for Trial Assessing Gene Therapy SGT-212 in Friedreich Ataxia

January 8th 2025

Expanding the Clinical Care of Friedreich Ataxia Through Omaveloxlone and SKYCLARYS PASS Registry
Expanding the Clinical Care of Friedreich Ataxia Through Omaveloxlone and SKYCLARYS PASS Registry

January 4th 2025

Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.